A research team from the Johns Hopkins Kimmel Cancer Center, its Bloomberg~Kimmel Institute for Cancer Immunotherapy and the ...
A research team from the Johns Hopkins Kimmel Cancer Center, its Bloomberg~Kimmel Institute for Cancer Immunotherapy and the ...
Despite improvements in therapies, multiple myeloma (MM) is a disease that will always relapse. Why is this? What is the key to finding effective therapies to cure MM? Evan Newell, a Professor in the ...
A new strategy strengthens the bond between the T cell and a target tumor cell, improving the cytotoxic function of the T cell.
Sickle cell disease (SCD) altered CD8+ T-cell chromatin architecture, triggering ferroptosis and weakening antitumor immunity. Hydrogen sulfide (H2S) treatment restored chromatin interactions and ...
CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...
Researchers have discovered how mitochondrial stress drives T cell exhaustion and a potential way to restore their ...
The current path to CAR-T cell therapy is, by any measure, a logistical ordeal. A patient’s immune cells must be drawn out of ...
A collaborative effort among researchers at the Henan Academy of Innovations in Medical Science, Zhengzhou University, and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results